Akero’s Phase II Success Could Augur Brighter Days For NASH R&D

 
• By Joseph Haas
  
NASH race
Akero is emerging as a co-favorite with Madrigal in NASH R&D • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business